Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revelation Biosciences Inc REVB

Healthcare Biotechnology
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its... see more

Recent & Breaking News (NDAQ:REVB)

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

Business Wire May 22, 2023

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

Business Wire March 30, 2023

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

Business Wire March 13, 2023

Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

Business Wire March 6, 2023

Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

Business Wire February 13, 2023

Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering

Business Wire February 9, 2023

Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300

Business Wire February 7, 2023

Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders

Business Wire January 31, 2023

Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023

Business Wire January 10, 2023

Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

Business Wire November 18, 2022

Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress

Business Wire November 10, 2022

Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease

Business Wire October 25, 2022

Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement

Business Wire October 6, 2022

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress

GlobeNewswire August 15, 2022

Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering

GlobeNewswire July 29, 2022

Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering

GlobeNewswire July 26, 2022

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

GlobeNewswire July 22, 2022

Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

GlobeNewswire July 14, 2022

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis 

GlobeNewswire June 13, 2022

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

GlobeNewswire May 23, 2022